Ronald J. Shebuski,Stephen R. Hanson,Christopher F. Toombs
申请号：
US15447073
公开号：
US20170252447A1
申请日:
2017.03.01
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A novel treatment for dialysis patients needing a hemodialysis graft by providing a therapeutic formulation that can be infused to such patients, which may mitigate graft-related neointimal hyperplasia, thrombosis, and/or related mechanisms of graft failure. The therapeutic formulation may include sirolimus and/or other olimus drug(s). The therapeutic formulation may be infusible and stable in solution for such a pharmaceutical and therapeutic purpose. The therapeutic formulation may have a pharmaceutically acceptable shelf life such that the pharmaceutical agent remains chemically stable (e.g., does not precipitate) for a suitable number of days (e.g., at least 30 days, at least 60 days, at least 90 days, etc.) at 37° C. The therapeutic formulation may be suitable for application to a patients blood vessel/vascular graft via an infusion pump. For instance, the therapeutic formulation may be suitable for application to the patients hemodialysis graft location.
